Drug Profile
Research programme: anti-inflammatory agents - Telik/SRI International
Alternative Names: Autoimummune disorder therapy - Telik/SRI International; C243Latest Information Update: 21 Jul 2010
Price :
$50
*
At a glance
- Originator Telik
- Developer SRI International; Telik
- Class Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Multiple sclerosis
Most Recent Events
- 31 Dec 2009 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 31 Dec 2009 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 31 Dec 2009 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)